Guerbet Launch Solar Project to Power 18% of Pharmaceutical Operations in Dublin

  • 4MW solar farm will meet 18% of the company’s total electricity requirements
  • Guerbet marks 30 years of operation in Ireland, employing over 130 skilled workers and selected Dublin as the site for its first solar farm
  • Every second a patient undergoes an imaging procedure with a Guerbet product

Dublin, 15th February 2024: Guerbet, a pioneer global pharmaceutical company specializing in medical imaging and contrast agents, has launched its first solar farm at its API manufacturing site in Dublin, coinciding with the celebration of its 30th year in operation.

2.4MW solar farm will meet 18% of the company’s total electricity requirements:

Guerbet entered a contract with Enerpower by Greenvolt*, a leading renewable energy company, for the construction of a 2.4MW solar farm at the Guerbet site in Damastown in 2022.

The two companies entered into a Corporate Power Purchase Agreement where Guerbet has guaranteed to purchase the solar PV electrical power for a period of 20 years. The solar farm is constructed on land owned by Guerbet and will provide the equivalent to the electricity consumption of 500 households.

The project will deliver 18% of the site’s electrical power on an annualised basis, and during the peak summer months could potentially power the plant without addition of electricity from the grid during daylight hours. 

The initiative aligns with Guerbet's strategy and its People and Planet Corporate Social Responsibility positioning for reducing carbon footprint as it looks forward to the next 30 years.

David Hale, CEO of Guerbet Group indicates: “At Guerbet, our purpose is ‘Building lasting relationships that enable people to live better’, and preserving our planet is a foundational part of that purpose.  In 2023, we made a commitment validated by the Science Based Targets Initiative (SBTi) to reduce our carbon emissions by 27,5% for Scope 1+2 and 13,5% for Scope 3 by 2032. Our partnership with Enerpower by Greenvolt is a great example of a relationship that will help us achieve those objectives.”

David Forde, Site Lead at Guerbet Dublin said: “Guerbet has a long history of innovation, growth, and service in the pharmaceutical industry. This new Corporate Power Purchase Agreement will produce renewable electricity for our API manufacturing site in Damastown and is a significant development in our long-term strategy to significantly reduce carbon emissions at the site. Guerbet joined the Science Based Targets Initiative (SBTi) which encourages ambitious climate action in the private sector by allowing companies to set science-based emission reduction targets. This is a further step on that journey.”

It also comes as the company celebrates 30-years of operation in Ireland. Over the past three decades, Guerbet has continuously strived for excellence, delivering cutting-edge medical imaging solutions and contrast agents to healthcare professionals worldwide, as well as offering highly skilled employment in the area.”

Guerbet marks 30 years of operation in Ireland, employing over 130 skilled workers:

The site in Dublin began production in 1994 and currently boasts a workforce of over 130 skilled professionals at the Damastown location. This local presence contributes to the company's global footprint, which spans across the 5 continents with 2,830 employees worldwide.

Guerbet develops and manufacture contrast media, which are instrumental in improving the visibility of internal organs, blood vessels, and tissues during medical imaging procedures.

Every second, somewhere in the world a patient undergoes an imaging procedure with a Guerbet product. More than 60,000 health professionals rely on the contrast agents to diagnose disease and assess treatment efficacy.


Issued by Murray on behalf of Guerbet

Jackie Phelan, Murray,, 083-8597874

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 98 years, with more than 2,830 employees worldwide, we continuously innovate and devote 10% of our revenue to research and development in five centers in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €785 million in revenue in 2023. For more information, please visit


* : "Guerbet assumes no responsibility for the information presented on this external website".


Contacts : 


Claire Lauvernier, Group Communication Director + /